Loading
The trial meant to settle a thirty-year argument: whether men whose germ cell tumour comes back after cisplatin should get standard salvage chemotherapy or high-dose chemotherapy with a stem cell transplant.
Relapsed germ cell tumours are still curable, but retrospective comparisons have long suggested that high-dose chemotherapy with stem cell rescue beats conventional-dose salvage, without a randomised proof. TIGER, run by the Alliance with European cooperative groups, randomises patients at first relapse between four cycles of TIP and the TI-CE high-dose programme. It is active and no longer recruiting, with overall survival as the primary endpoint. Patients with primary mediastinal non-seminoma, the poorest-risk extragonadal group, are among those most in need of the answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifosfamide and the tag owner-request.
Shares Mediastinal germ cell tumour, Extragonadal germ cell tumour, Non-seminomatous germ cell tumour, Testicular germ cell tumours.
Shares Non-seminomatous germ cell tumour, Ifosfamide, Testicular germ cell tumours, Etoposide.
Shares Choriocarcinoma of the testis, Non-seminomatous germ cell tumour, Testicular germ cell tumours, Etoposide.
Shares Choriocarcinoma of the testis, Non-seminomatous germ cell tumour, Testicular germ cell tumours, Etoposide.
Shares Extragonadal germ cell tumour, Testicular germ cell tumours, Etoposide, Cisplatin.
Shares Ifosfamide, Testicular germ cell tumours, Etoposide, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/